| Budget Amount *help |
¥85,540,000 (Direct Cost: ¥65,800,000、Indirect Cost: ¥19,740,000)
Fiscal Year 2019: ¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2018: ¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2017: ¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2016: ¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2015: ¥18,980,000 (Direct Cost: ¥14,600,000、Indirect Cost: ¥4,380,000)
|
|---|
| Outline of Final Research Achievements |
We have synthesized many glycans and glycoconjugates. We also evaluate their biological functions. In this study, we developed a highly efficient method for the synthesis of useful glycans and glycoconjugates using integrated synthesis to achieve a quantitative supply of these compounds. Immunological function of synthesized compounds was also evaluated. In addition, we created various glycoconjugates, including cancer vaccines. These functional-integrated middle molecules have emergent functions. These compounds are expected to be the seeds of next-generation drugs. These studies were carried out in collaboration with a number of researchers.
|
